Rotavirus gastroenteritis: Why to back up the development of new vaccines?

Comparative Immunology, Microbiology and Infectious Diseases

Volumn 31, Issue 2-3, 2008, Pages 253-269

  Parez, Nathalie ^a  

^a ARMAND TROUSSEAU HOSPITAL   (France)

Author keywords

Children; Diarrhoea; Rotavirus; Vaccines

Indexed keywords

DNA VACCINE; IMMUNOGLOBULIN G; INACTIVATED VIRUS VACCINE; LIVE VACCINE; POLIOMYELITIS VACCINE; PROTEIN VP1; PROTEIN VP2; PROTEIN VP3; ROTAVIRUS NONSTRUCTURAL PROTEIN 4; ROTAVIRUS VACCINE; SUBUNIT VACCINE; VIRUS ANTIBODY; VIRUS RNA;

ACUTE DIARRHEA; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DIARRHEA; DNA IMMUNIZATION; DRUG COMPETITION; DRUG COST; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; IMMUNIZATION; INFECTION PREVENTION; INFECTION RISK; INTESTINE INTUSSUSCEPTION; INTUSSUSCEPTION; MUCOSAL IMMUNITY; NONHUMAN; ORAL REHYDRATION THERAPY; POLIOMYELITIS; PREVALENCE; ROTAVIRUS; VACCINATION; VACCINE PRODUCTION; VIRAL GASTROENTERITIS; VIRUS IMMUNITY; VIRUS LIKE AGENT; VIRUS PATHOGENESIS; VIRUS TRANSMISSION;

GASTROENTERITIS; HUMANS; ROTAVIRUS; ROTAVIRUS INFECTIONS; VIRAL VACCINES;

ANIMALIA; ROTAVIRUS;

EID: 39849099651     PISSN: 01479571     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cimid.2007.07.005     Document Type: Article

References (57)

1. Parashar U.D., Gibson C.J., Bresse J.S., and Glass R.I. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 12 (2006) 304-306
2. Butz A.M., Fosarelli P., Dick J., Cusack T., and Yolken R. Prevalence of rotavirus on high-risk fomites in day-care facilities. Pediatrics 92 (1993) 202-205
3. Anderson E.J., and Weber S.G. Rotavirus infection in adults. Lancet Infect Dis 4 (2004) 91-99
4. Pickering L.K., Evans D.G., DuPont H.L., Vollet J.J., and Evans D.J. Diarrhea caused by shigella, rotavirus, and giardia in day-care centers: prospective study. J Pediatr 99 (1981) 51-56
5. Vollet J.J., Ericsson C.D., Gibson G., et al. Human rotavirus in an adult population with travelers' diarrhea and its relationship to the location of food consumption. J Med Virol 4 (1979) 81-87
6. Marshall J., Botes J., Gorrie G., et al. Rotavirus detection and characterisation in outbreaks of gastroenteritis in aged-care facilities. J Clin Virol 28 (2003) 331-340
7. Richardson S., Grimwood K., Gorrell R., Palombo E., Barnes G., and Bishop R. Extended excretion of rotavirus after severe diarrhoea in young children. Lancet 351 (1998) 1844-1848
8. Fischer T.K., Bresee J.S., and Glass R.I. Rotavirus vaccines and the prevention of hospital-acquired diarrhea in children. Vaccine 22 Suppl 1 (2004) S49-S54
9. Koopmans M., and Brown D. Seasonality and diversity of Group A rotaviruses in Europe. Acta Paediatr Suppl 88 (1999) 14-19
10. Dennehy P.H. Transmission of rotavirus and other enteric pathogens in the home. Pediatr Infect Dis J 19 (2000) S103-S105
11. Gleizes O., Desselberger U., Tatochenko V., et al. Nosocomial rotavirus infection in European countries: a review of the epidemiology, severity and economic burden of hospital-acquired rotavirus disease. Pediatr Infect Dis J 25 (2006) S12-S21
12. Grimprel E., Parez N., Gault E., Garbarg-Chenon A., and Begue P. Acute diarrhea and rotavirus infection in the child: assessment of data from emergency care and and the microbiology laboratory of the Armand-Trousseau (Paris) Hospital between 1988 and 2001. Arch Pediatr 8 (2001) 1318-1324
13. Staat M.A., Azimi P.H., Berke T., et al. Clinical presentations of rotavirus infection among hospitalized children. Pediatr Infect Dis J 21 (2002) 221-227
14. Rodriguez W.J., Kim H., Arrobio J.O., et al. Clinical features of acute gastroenteritis associated with human reovirus-like agent in infants and young children. J Pediatr 91 (1977) 188-193
15. Pang X.L., Joensuu J., and Vesikari T. Detection of rotavirus RNA in cerebrospinal fluid in a case of rotavirus gastroenteritis with febrile seizures. Pediatr Infect Dis J 15 (1996) 543-545
16. Dennehy P.H., Cortese M.M., Begue R.E., et al. A case-control study to determine risk factors for hospitalization for rotavirus gastroenteritis in US children. Pediatr Infect Dis J 25 (2006) 1123-1131
17. Newman R.D., Grupp-Phelan J., Shay D.K., and Davis R.L. Perinatal risk factors for infant hospitalization with viral gastroenteritis. Pediatrics 103 (1999) E3
18. Estes M. Rotaviruses and their replication. In: Knipe D.M., et al. (Ed). Fields virology. 4th ed (2001), Lippincott Wiliams & Wilkins, Philadelphia 1747-1785
19. Schwartz-Cornil I., Benureau Y., Greenberg H., Hendrickson B.A., and Cohen J. Heterologous protection induced by the inner capsid proteins of rotavirus requires transcytosis of mucosal immunoglobulins. J Virol 76 (2002) 8110-8117
20. Feng N., Lawton J.A., Gilbert J., et al. Inhibition of rotavirus replication by a non-neutralizing, rotavirus VP6-specific IgA mAb. J Clin Invest 109 (2002) 1203-1213
21. Santos N., and Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol 15 (2005) 29-56
22. Gentsch J.R., Woods P.A., Ramachandran M., et al. Review of G and P typing results from a global collection of rotavirus strains: implications for vaccine development. J Infect Dis 174 Suppl 1 (1996) S30-S36
23. Khamrin P., Maneekarn N., Peerakome S., Yagyu F., Okitsu S., and Ushijima H. Molecular characterization of a rare G3P[3] human rotavirus reassortant strain reveals evidence for multiple human-animal interspecies transmissions. J Med Virol 78 (2006) 986-994
24. Parez N., Garbarg-Chenon A., Fourgeux C., et al. The VP6 protein of rotavirus interacts with a large fraction of human naive B cells via surface immunoglobulins. J Virol 78 (2004) 12489-12496
25. Westerman L.E., McClure H.M., Jiang B., Almond J.W., and Glass R.I. Serum IgG mediates mucosal immunity against rotavirus infection. Proc Natl Acad Sci USA 102 (2005) 7268-7273
26. Jiang B., Gentsch J.R., and Glass R.I. The role of serum antibodies in the protection against rotavirus disease: an overview. Clin Infect Dis 34 (2002) 1351-1361
27. Kaufhold R.M., Field J.A., Caulfield M.J., et al. Memory T-cell response to rotavirus detected with a gamma interferon enzyme-linked immunospot assay. J Virol 79 (2005) 5684-5694
28. Jaimes M.C., Feng N., and Greenberg H.B. Characterization of homologous and heterologous rotavirus-specific T-cell responses in infant and adult mice. J Virol 79 (2005) 4568-4579
29. Sestak K., McNeal M.M., Choi A., et al. Defining T-cell-mediated immune responses in rotavirus-infected juvenile rhesus macaques. J Virol 78 (2004) 10258-10264
30. McNeal M.M., Rae M.N., and Ward R.L. Evidence that resolution of rotavirus infection in mice is due to both CD4 and CD8 cell-dependent activities. J Virol 71 (1997) 8735-8742
31. Makela M., Marttila J., Simell O., and Ilonen J. Rotavirus-specific T-cell responses in young prospectively followed-up children. Clin Exp Immunol 137 (2004) 173-178
32. Bishop R.F., Barnes G.L., Cipriani E., and Lund J.S. Clinical immunity after neonatal rotavirus infection. A prospective longitudinal study in young children. N Engl J Med 309 (1983) 72-76
33. Velazquez F.R., Matson D.O., Calva J.J., et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 335 (1996) 1022-1028
34. Bernstein D.I., Sander D.S., Smith V.E., Schiff G.M., and Ward R.L. Protection from rotavirus reinfection: 2-year prospective study. J Infect Dis 164 (1991) 277-283
35. Clark H.F., Borian F.E., Bell L.M., Modesto K., Gouvea V., and Plotkin S.A. Protective effect of WC3 vaccine against rotavirus diarrhea in infants during a predominantly serotype 1 rotavirus season. J Infect Dis 158 (1988) 570-587
36. Vesikari T., Isolauri E., d'Hondt E., Delem A., Andre F.E., and Zissis G. Protection of infants against rotavirus diarrhoea by RIT 4237 attenuated bovine rotavirus strain vaccine. Lancet 1 (1984) 977-981
37. Bernstein D.I., Glass R.I., Rodgers G., Davidson B.L., and Sack D.A. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. US Rotavirus Vaccine Efficacy Group. JAMA 273 (1995) 1191-1196
38. C.D.C. From the Centers for Disease Control and Prevention. Recommended childhood immunization schedule-United States, 1999. JAMA 281 (1999) 601-603
39. C.D.C. Withdrawal of rotavirus vaccine recommendation. MMWR Morb Mortal Wkly Rep 48 (1999) 1007
40. Ruiz-Palacios G.M., Perez-Schael I., Velazquez F.R., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 354 (2006) 11-22
41. Vesikari T., Karvonen A.V., Majuri J., et al. Safety, efficacy, and immunogenicity of 2 doses of bovine-human (UK) and rhesus-rhesus-human rotavirus reassortant tetravalent vaccines in Finnish children. J Infect Dis 194 (2006) 370-376
42. Vesikari T., Matson D.O., Dennehy P., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 354 (2006) 23-33
43. Simonsen L., Morens D., Elixhauser A., Gerber M., Van Raden M., and Blackwelder W. Effect of rotavirus vaccination programme on trends in admission of infants to hospital for intussusception. Lancet 358 (2001) 1224-1229
44. Murphy T.V., Gargiullo P.M., Massoudi M.S., et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 344 (2001) 564-572
45. Pichichero M.E. Effect of breast-feeding on oral rhesus rotavirus vaccine seroconversion: a metaanalysis. J Infect Dis 162 (1990) 753-755
46. Ciarlet M., Crawford S.E., Barone C., et al. Subunit rotavirus vaccine administered parenterally to rabbits induces active protective immunity. J Virol 72 (1998) 9233-9246
47. Choi A.H., Smiley K., and Basu M. Induction of immune responses and partial protection in mice after skin immunization with rotavirus VP6 protein and the adjuvant LT(R192G). Vaccine 23 (2005) 2290-2293
48. Parez N., Fourgeux C., Mohamed A., et al. Rectal immunization with rotavirus virus-like particles induces systemic and mucosal humoral immune responses and protects mice against rotavirus infection. J Virol 80 (2006) 1752-1761
49. Herrmann J.E. DNA vaccines against enteric infections. Vaccine 24 (2006) 3705-3708
50. McNeal M.M., Stone S.C., Basu M., et al. Protection against rotavirus shedding after intranasal immunization of mice with a chimeric VP6 protein does not require intestinal IgA. Virology 346 (2006) 338-347
51. Choi A.H., McNeal M., Basu M., et al. Intranasal or oral immunization of inbred and outbred mice with murine or human rotavirus VP6 proteins protects against viral shedding after challenge with murine rotaviruses. Vaccine 20 (2002) 3310
52. McNeal M.M., Rae M.N., and Ward R.L. Effects of different adjuvants on rotavirus antibody responses and protection in mice following intramuscular immunization with inactivated rotavirus. Vaccine 17 (1999) 1573-1580
53. Johansen K., Schroder U., and Svensson L. Immunogenicity and protective efficacy of a formalin-inactivated rotavirus vaccine combined with lipid adjuvants. Vaccine 21 (2003) 368-375
54. Blutt S.E., Warfield K.L., O'Neal C.M., Estes M.K., and Conner M.E. Host, viral, and vaccine factors that determine protective efficacy induced by rotavirus and virus-like particles (VLPs). Vaccine 24 (2006) 1170-1179
55. Shuttleworth G., Eckery D.C., and Awram P. Oral and intraperitoneal immunization with rotavirus 2/6 virus-like particles stimulates a systemic and mucosal immune response in mice. Arch Virol 150 (2005) 341-349
56. Bertolotti-Ciarlet A., Ciarlet M., Crawford S.E., Conner M.E., and Estes M.K. Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice. Vaccine 21 (2003) 3885-3900
57. Soriano-Gabarro M., Mrukowicz J., Vesikari T., and Verstraeten T. Burden of rotavirus disease in European Union countries. Pediatr Infect Dis J 25 (2006) S7-S11